Insider · CIK 0001238362

MENDLEIN JOHN

Reports to the SEC for 7 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001238362

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-05-29	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+55K sh	—	—	55,000
2024-06-20	Omega Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2024-06-07	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2023-06-07	Omega Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+18.1K sh	—	—	18,118
2023-06-06	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2023-01-19	FATEFATE THERAPEUTICS INCM Exercise/Conversion	Director	MExercise/Conversion	+28.5K sh	$1.37	+$39K	311,231
2023-01-19	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	+28.5K sh	—	—	0
2023-01-13	FATEFATE THERAPEUTICS INCP Purchase	Director	PPurchase	+36.6K sh	$5.43	+$199K	282,770
2023-01-11	FATEFATE THERAPEUTICS INCP Purchase	Director	PPurchase	+88K sh	$5.67	+$499K	246,139
2022-06-09	FATEFATE THERAPEUTICS INCA Award	Director	AAward	+8,650 sh	—	—	166,741
2022-06-09	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+11.9K sh	—	—	11,893
2022-06-08	Omega Therapeutics, Inc.Option (Right to Buy)A Award	Director	AAward	+18.1K sh	—	—	18,118
2022-06-03	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	−1,364 sh	$22.79	−$31.1K	158,091
2022-03-10	FATEFATE THERAPEUTICS INCM Exercise/Conversion	Director	MExercise/Conversion	+31.6K sh	$1.63	+$51.4K	191,017
2022-03-10	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	−19.5K sh	$34.73	−$677K	171,524
2022-03-10	FATEFATE THERAPEUTICS INCS Sale	Director	SSale	−12.1K sh	$35.48	−$428K	159,455
2022-03-10	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−31.6K sh	—	—	0
2021-06-02	FATEFATE THERAPEUTICS INCA Award	Director	AAward	+2,681 sh	—	—	159,455
2021-06-02	FATEFATE THERAPEUTICS INC · Stock Option (Right to Buy)A Award	Director	AAward	+4,334 sh	—	—	4,334
2020-05-01	FATEFATE THERAPEUTICS INC · Stock Option (right to buy)A Award	Director	AAward	+16K sh	—	—	16,000
2019-05-08	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-05-03	FATEFATE THERAPEUTICS INC · Stock Option (right to buy)A Award	Director	AAward	+16K sh	—	—	16,000
2018-12-21	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+195K sh	$0.42	+$82.6K	615,382
2018-12-20	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+50K sh	$0.41	+$20.6K	420,382
2018-05-15	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2018-05-02	FATEFATE THERAPEUTICS INC · Stock Option (right to buy)A Award	Director	AAward	+16K sh	—	—	16,000
2018-01-02	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+32K sh	—	—	32,000
2017-08-31	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+37.7K sh	$2.65	+$100K	367,883
2017-08-31	ATYRaTYR PHARMA INC · Warrant to Purchase Common StockP Purchase	Director	PPurchase	+14.2K sh	—	—	14,151
2017-06-15	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+11.5K sh	—	—	11,538
2017-05-02	FATEFATE THERAPEUTICS INC · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2017-04-24	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+124 sh	$3.00	+$372	327,647
2017-04-20	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+1,552 sh	$3.00	+$4,656	327,523
2017-04-18	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+1,000 sh	$3.00	+$3,000	325,971
2017-02-07	ATYRaTYR PHARMA INC · Employee Stock Option (right to buy)A Award	Director	AAward	+185K sh	—	—	185,000
2016-12-19	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+69K sh	$2.20	+$152K	324,971
2016-05-11	FATEFATE THERAPEUTICS INC · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2016-04-05	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+2,500 sh	$3.52	+$8,800	250,971
2016-04-05	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+2,500 sh	$3.55	+$8,875	248,471
2016-02-03	EDITEditas Medicine, Inc. · Stock Option (right to buy)A Award	Director	AAward	+96.2K sh	—	—	96,153
2016-01-27	ATYRaTYR PHARMA INC · Employee Stock Option (right to buy)A Award	Director	AAward	+135K sh	—	—	135,000
2016-01-04	ATYRaTYR PHARMA INC · Employee Stock Option (right to buy)A Award	Director	AAward	+149K sh	—	—	148,732
2015-10-01	ATYRaTYR PHARMA INC · Employee Stock Option (right to buy)A Award	Director	AAward	+71K sh	—	—	71,000
2015-10-01	ATYRaTYR PHARMA INC · Employee Stock Option (right to buy)A Award	Director	AAward	+65.1K sh	—	—	65,070
2015-05-13	FATEFATE THERAPEUTICS INC · Stock Option (right to buyA Award	Director	AAward	+10K sh	—	—	10,000
2015-05-12	ATYRaTYR PHARMA INCC Conversion	Director	CConversion	+24.1K sh	—	—	245,971
2015-05-12	ATYRaTYR PHARMA INC · Series C Redeemable Convertible Preferred StockC Conversion	Director	CConversion	−170K sh	—	—	0
2015-05-12	ATYRaTYR PHARMA INC · Series D Redeemable Convertible Preferred StockC Conversion	Director	CConversion	−21.1K sh	—	—	0
2015-05-06	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+163K sh	—	—	163,437
2013-10-04	FATEFATE THERAPEUTICS INCP Purchase	Director	PPurchase	+16.7K sh	$6.00	+$100K	156,774

Recent filings

Accepted (ET)
May 304
MENDLEIN JOHN0000950170-25-079716
SEC(opens sec.gov)
Jun 214
MENDLEIN JOHN0000950170-24-076264
SEC(opens sec.gov)
Jun 114
MENDLEIN JOHN0000950170-24-071941
SEC(opens sec.gov)
Jun 94
MENDLEIN JOHN0000899243-23-015149
SEC(opens sec.gov)
Jun 74
MENDLEIN JOHN0001209191-23-035059
SEC(opens sec.gov)
Jan 204
MENDLEIN JOHN0001209191-23-004237
SEC(opens sec.gov)
Jan 134
MENDLEIN JOHN0001209191-23-003338
SEC(opens sec.gov)
Jun 134
MENDLEIN JOHN0001209191-22-036350
SEC(opens sec.gov)
Jun 104
MENDLEIN JOHN0000899243-22-021897
SEC(opens sec.gov)
Jun 64
MENDLEIN JOHN0001209191-22-034554
SEC(opens sec.gov)
Mar 114
MENDLEIN JOHN0001209191-22-018188
SEC(opens sec.gov)
Jun 44
MENDLEIN JOHN0000899243-21-022076
SEC(opens sec.gov)
May 54
MENDLEIN JOHN0001209191-20-027100
SEC(opens sec.gov)

Companies

Address

C/O MONOGRAM BIOSCIENCES, INC. 345 OYSTER POINT BOULEVARD

SOUTH SAN FRANCISCO, CA, 94080